Article Text

Download PDFPDF
Ximelagatran was not inferior to warfarin for preventing stroke and systemic embolism in non-valvular atrial fibrillation

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • * See glossary.

  • For correspondence: Dr J L Halperin, Mount Sinai Medical Center, New York, NY, USA;

  • Source of funding: Astra-Zeneca.